JP2021521781A5 - - Google Patents

Info

Publication number
JP2021521781A5
JP2021521781A5 JP2020557151A JP2020557151A JP2021521781A5 JP 2021521781 A5 JP2021521781 A5 JP 2021521781A5 JP 2020557151 A JP2020557151 A JP 2020557151A JP 2020557151 A JP2020557151 A JP 2020557151A JP 2021521781 A5 JP2021521781 A5 JP 2021521781A5
Authority
JP
Japan
Prior art keywords
domain
amino acid
sequence
acid sequence
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020557151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521781A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027816 external-priority patent/WO2019204398A1/en
Publication of JP2021521781A publication Critical patent/JP2021521781A/ja
Publication of JP2021521781A5 publication Critical patent/JP2021521781A5/ja
Pending legal-status Critical Current

Links

JP2020557151A 2018-04-17 2019-04-17 三価三重特異性抗体構築物 Pending JP2021521781A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659047P 2018-04-17 2018-04-17
US62/659,047 2018-04-17
PCT/US2019/027816 WO2019204398A1 (en) 2018-04-17 2019-04-17 Trivalent trispecific antibody constructs

Publications (2)

Publication Number Publication Date
JP2021521781A JP2021521781A (ja) 2021-08-30
JP2021521781A5 true JP2021521781A5 (enExample) 2022-04-22

Family

ID=68240367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020557151A Pending JP2021521781A (ja) 2018-04-17 2019-04-17 三価三重特異性抗体構築物

Country Status (10)

Country Link
US (2) US20210179734A1 (enExample)
JP (1) JP2021521781A (enExample)
KR (1) KR20200143730A (enExample)
CN (1) CN112384243A (enExample)
AU (1) AU2019255270A1 (enExample)
BR (1) BR112020021279A2 (enExample)
CA (1) CA3097605A1 (enExample)
IL (1) IL278073A (enExample)
MX (1) MX2020011027A (enExample)
WO (1) WO2019204398A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348603B (zh) * 2015-11-03 2023-12-29 Ambrx公司 抗cd3叶酸结合物和其用途
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
AU2021304372A1 (en) * 2020-07-10 2023-03-02 Biomolecular Holdings Llc Tetrahedral antibodies
US20240228588A1 (en) * 2021-01-11 2024-07-11 Adimab, Llc Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same
AU2022215712A1 (en) * 2021-02-07 2023-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
TW202506725A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 三特異性工程化抗體
EP4702058A2 (en) * 2023-04-28 2026-03-04 Xencor, Inc. Orthogonal multimeric proteins
EP4777539A1 (en) * 2023-09-11 2026-07-22 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN110437337B (zh) * 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
SG10202107077QA (en) * 2014-04-02 2021-07-29 Hoffmann La Roche Method for detecting multispecific antibody light chain mispairing
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
ES2808853T3 (es) * 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
JP7021955B2 (ja) * 2015-06-24 2022-03-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
US20170096485A1 (en) * 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
CN109069633A (zh) * 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2021522162A5 (enExample)
JP2019534277A5 (enExample)
JP2018537966A5 (enExample)
JP2020531438A5 (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質
JP2023085476A5 (enExample)
JP2022512234A5 (enExample)
JP2021533779A5 (enExample)
JP2021098732A5 (enExample)
JP2019502712A5 (enExample)
JP2021534096A5 (enExample)
JP2019533441A5 (enExample)
JP2024150674A5 (enExample)
JP2024534545A5 (enExample)
JP2022551969A5 (enExample)
JP2025111463A5 (enExample)
JP2020519643A5 (enExample)
IL274071B2 (en) Method for generating in vivo multispecific antibodies from monospecific antibodies
JP2021533159A5 (enExample)
JP2018522541A5 (enExample)
JP2018502050A5 (enExample)
JP2005510246A5 (enExample)
JP2017537896A5 (enExample)
JP2024532489A5 (enExample)
JPWO2021241616A5 (enExample)
US20260078202A1 (en) Orthogonal mutations for heterodimerization